PARP inhibitor biomarkers are used for tissue analysis and molecular profiling to identify homologous recombination deficiency (HRD) positive cancers. These biomarkers help doctors determine a patient's sensitivity to PARP inhibitor drugs. They play a vital role in cancer treatment and targeted therapy selection. The detection of HRD positive cancers allows more effective PARP inhibitor therapies to be designed for patients. The global PARP inhibitor biomarkers market is estimated to be ... Read more
